<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Health Prescription Drug User Fee Act Center for Biologics Evaluation and Research Biosimilar FDA Special Protocol Assessment New Drug Application Generic drug Center for Drug Evaluation and Research Biologic Food and Drug Administration Pharmaceutical sciences Medicine |
Add to Reading List |
Microsoft Word - 16618dft.doc | Microsoft Word - Savient press release Puricase SPAdocDocID: 1qW9f - View Document |
| Microsoft Word - Savient Announces FDA Advisory PaneldocDocID: 1q0EW - View Document |
| Microsoft Word - 9124dft.docDocID: 1ak2h - View Document |
| ACUSPHERE INC. REACHES SPECIAL PROTOCOL ASSESSMENT AGREEMENT WITH FDA FOR IMAGIFY™ PHASE 3 PLACEBO-CONTROLLED TRIAL LEXINGTON, MASS., June 8, [removed]Acusphere, Inc. (ACUS.PK), a specialty pharmaceutical company, todayDocID: YRPF - View Document |
| Microsoft Word - StarpharmadocxDocID: Wa8v - View Document |